{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:00:16Z","timestamp":1794024016517,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnancy may disrupt physiological maternal immune adaptations, thereby altering fetal immune programming and increasing the long-term risk of autoimmune diseases (ADs) in offspring. This is a pressing public health concern, as both maternal MASLD and childhood-onset ADs are rising in prevalence worldwide. This nationwide cohort study included all singleton live-born offspring of mothers with biopsy-proven MASLD diagnosed in Sweden between 1992 and 2017. We matched the 239 identified MASLD offspring with up to\u20095 reference offspring (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091,131) of mothers without known MASLD by maternal age at delivery, calendar year of delivery, and parity. We used multivariable Cox proportional hazard models to estimate adjusted hazard ratios (aHRs) for any AD up until 2023. We performed stratified analyses by histological stage of maternal MASLD (simple steatosis versus severe MASLD defined as either steatohepatitis, any stage of liver fibrosis, or cirrhosis). During a median of 18.4 years of follow-up (interquartile range [IQR] 13.2\u201323.8), 15 exposed offspring (incidence rate [IR] 3.4\/1000 person-years) vs. 40 reference offspring (IR 1.9\/1000 person-years) were diagnosed with AD. This corresponded to an aHR of 1.20 (95% CI 0.57\u20132.53). The risk of AD remained unchanged among 175 offspring born to mothers with simple steatosis (aHR 0.84, 95% CI 0.29\u20132.45), and was higher, but not significant, in 64 offspring of mothers with severe MASLD (aHR 1.98, 95% CI 0.67\u20135.84). We did not identify an association of maternal MASLD with AD in offspring. Larger studies with follow-up extending beyond early adulthood are, however, needed.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-46246-x","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:48:32Z","timestamp":1775713712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Autoimmune disease in offspring of mothers with metabolic dysfunction-associated steatotic liver disease (MASLD): a nationwide cohort study"],"prefix":"10.1038","volume":"16","author":[{"given":"Carole A.","family":"Marxer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahim","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Thuresson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Stephansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas F.","family":"Ludvigsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"46246_CR1","doi-asserted-by":"publisher","unstructured":"Sarkar, M. & Kushner, T. Metabolic dysfunction\u2013associated steatotic liver disease and pregnancy. J. Clin. Invest.135 (10). https:\/\/doi.org\/10.1172\/JCI186426 (May 2025).","DOI":"10.1172\/JCI186426"},{"key":"46246_CR2","doi-asserted-by":"publisher","unstructured":"Sarkar, M. et al. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology73 (1), 318\u2013365. https:\/\/doi.org\/10.1002\/hep.31559 (Jan. 2021).","DOI":"10.1002\/hep.31559"},{"key":"46246_CR3","doi-asserted-by":"publisher","unstructured":"Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A. J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology67 (1), 123\u2013133. https:\/\/doi.org\/10.1002\/HEP.29466 (Jan. 2018).","DOI":"10.1002\/HEP.29466"},{"key":"46246_CR4","doi-asserted-by":"publisher","unstructured":"Allen, A. M. et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology67 (5), 1726\u20131736. https:\/\/doi.org\/10.1002\/HEP.29546 (May 2018).","DOI":"10.1002\/HEP.29546"},{"key":"46246_CR5","doi-asserted-by":"publisher","unstructured":"Vernon, G., Baranova, A. & Younossi, Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther.34 (3), 274\u2013285. https:\/\/doi.org\/10.1111\/J.1365-2036.2011.04724.X (Aug. 2011).","DOI":"10.1111\/J.1365-2036.2011.04724.X"},{"key":"46246_CR6","doi-asserted-by":"publisher","unstructured":"Sarkar, M. et al. Sep., Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes, J. Hepatol., vol. 73, no. 3, pp. 516\u2013522, (2020). https:\/\/doi.org\/10.1016\/J.JHEP.2020.03.049","DOI":"10.1016\/J.JHEP.2020.03.049"},{"key":"46246_CR7","doi-asserted-by":"publisher","unstructured":"Targher, G. et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 30 (5), 1212\u20131218. https:\/\/doi.org\/10.2337\/DC06-2247 (May 2007).","DOI":"10.2337\/DC06-2247"},{"key":"46246_CR8","doi-asserted-by":"publisher","first-page":"70174","DOI":"10.1111\/liv.70174","volume":"45","author":"CA Marxer","year":"2025","unstructured":"Marxer, C. A. et al. Mortality and Cancer in Offspring of Mothers With Biopsy-Proven MASLD During Pregnancy: A Nationwide Cohort Study. Liver Int.45, 70174. https:\/\/doi.org\/10.1111\/liv.70174 (2025).","journal-title":"Liver Int."},{"key":"46246_CR9","doi-asserted-by":"publisher","unstructured":"Marxer, C. A. & Ludvigsson, J. F. Response: Methodological Considerations for Assessing the Long-Term Impact of Maternal MASLD on Offspring Health. Liver Int.45 (8). https:\/\/doi.org\/10.1111\/LIV.70233 (Aug. 2025).","DOI":"10.1111\/LIV.70233"},{"key":"46246_CR10","doi-asserted-by":"publisher","unstructured":"Marxer, C. A. et al. Higher Risk of Serious Infection in Offspring of Mothers With Biopsy-Proven MASLD: A Nationwide Cohort Study. United Eur. Gastroenterol. J.14 (1), e70163. https:\/\/doi.org\/10.1002\/UEG2.70163 (Feb. 2026).","DOI":"10.1002\/UEG2.70163"},{"key":"46246_CR11","doi-asserted-by":"publisher","unstructured":"Williamson, C. et al. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy. J. Hepatol.79 (3), 768\u2013828. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.006 (Sep. 2023).","DOI":"10.1016\/j.jhep.2023.03.006"},{"key":"46246_CR12","doi-asserted-by":"publisher","unstructured":"Jee, Y. M., Lee, J. Y. & Ryu, T. Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma. Biomedicines 2025. 13, Page 1260, 13, (5), 1260. https:\/\/doi.org\/10.3390\/BIOMEDICINES13051260 (May 2025).","DOI":"10.3390\/BIOMEDICINES13051260"},{"key":"46246_CR13","doi-asserted-by":"publisher","unstructured":"Denizli, M., Capitano, M. L. & Kua, K. L. Maternal obesity and the impact of associated early-life inflammation on long-term health of offspring. Front. Cell. Infect. Microbiol.12, 940937. https:\/\/doi.org\/10.3389\/FCIMB.2022.940937\/PDF (Sep. 2022).","DOI":"10.3389\/FCIMB.2022.940937\/PDF"},{"key":"46246_CR14","doi-asserted-by":"publisher","unstructured":"Mor, G., Aldo, P. & Alvero, A. B. The unique immunological and microbial aspects of pregnancy, Nat. Rev. Immunol., vol. 17, no. 8, pp. 469\u2013482, Aug. (2017). https:\/\/doi.org\/10.1038\/NRI.2017.64","DOI":"10.1038\/NRI.2017.64"},{"key":"46246_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/J.THROMRES.2004.06.038","volume":"114","author":"NM Gude","year":"2004","unstructured":"Gude, N. M., Roberts, C. T., Kalionis, B. & King, R. G. Growth and function of the normal human placenta. Thromb. Res.114, 5\u20136. https:\/\/doi.org\/10.1016\/J.THROMRES.2004.06.038 (2004).","journal-title":"Thromb. Res."},{"key":"46246_CR16","doi-asserted-by":"publisher","unstructured":"Faas, M. M. & Smink, A. M. Shaping immunity: the influence of the maternal gut bacteria on fetal immune development, Seminars in Immunopathology 2025 47:1, vol. 47, no. 1, p. 13-, Feb. (2025). https:\/\/doi.org\/10.1007\/S00281-025-01039-8","DOI":"10.1007\/S00281-025-01039-8"},{"key":"46246_CR17","doi-asserted-by":"publisher","unstructured":"Conrad, N. et al. Jun., Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK, The Lancet, vol. 401, no. 10391, pp. 1878\u20131890, (2023). https:\/\/doi.org\/10.1016\/S0140-6736(23)00457-9","DOI":"10.1016\/S0140-6736(23)00457-9"},{"key":"46246_CR18","doi-asserted-by":"publisher","unstructured":"Xu, M., Wu, T., Li, Z. & Xin, G. Influence of genetically predicted autoimmune diseases on NAFLD. Front. Immunol.14https:\/\/doi.org\/10.3389\/FIMMU.2023.1229570 (2023).","DOI":"10.3389\/FIMMU.2023.1229570"},{"key":"46246_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/CLEP.S191914","volume":"11","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson, J. F. & Lashkariani, M. Cohort profile: ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden). Clin. Epidemiol.11, 101\u2013114. https:\/\/doi.org\/10.2147\/CLEP.S191914 (2019).","journal-title":"Clin. Epidemiol."},{"key":"46246_CR20","doi-asserted-by":"publisher","unstructured":"Ludvigsson, J. F., Otterblad-Olausson, P., Pettersson, B. U. & Ekbom, A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research, Eur. J. Epidemiol., vol. 24, no. 11, pp. 659\u2013667, Nov. (2009). https:\/\/doi.org\/10.1007\/S10654-009-9350-Y","DOI":"10.1007\/S10654-009-9350-Y"},{"key":"46246_CR21","doi-asserted-by":"publisher","unstructured":"Ludvigsson, J. F. & Lashkariani, M. Cohort Update: ESPRESSO (Epidemiology Strengthened by Histopathology Reports in Sweden). Clin. Epidemiol.17, 193\u2013196. https:\/\/doi.org\/10.2147\/CLEP.S499859 (Feb. 2025).","DOI":"10.2147\/CLEP.S499859"},{"key":"46246_CR22","doi-asserted-by":"publisher","unstructured":"Cnattingius, S. et al. The Swedish medical birth register during five decades: documentation of the content and quality of the register. Eur. J. Epidemiol.38 (1), 109\u2013120. https:\/\/doi.org\/10.1007\/S10654-022-00947-5 (Jan. 2023).","DOI":"10.1007\/S10654-022-00947-5"},{"key":"46246_CR23","doi-asserted-by":"publisher","unstructured":"Marxer, C. A. et al. Adverse pregnancy and birth outcomes in women with biopsy-proven MASLD: a nationwide cohort study. EClinicalMedicine 103238. https:\/\/doi.org\/10.1016\/J.ECLINM.2025.103238 (May 2025).","DOI":"10.1016\/J.ECLINM.2025.103238"},{"key":"46246_CR24","doi-asserted-by":"publisher","unstructured":"Hagstr\u00f6m, H. et al. Jul., Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement, Hepatology, vol. 74, no. 1, pp. 474\u2013482, (2021). https:\/\/doi.org\/10.1002\/HEP.31726","DOI":"10.1002\/HEP.31726"},{"key":"46246_CR25","doi-asserted-by":"publisher","unstructured":"Simon, T. G., Roelstraete, B., Khalili, H., Hagstr\u00f6m, H. & Ludvigsson, J. F. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort, Gut, vol. 70, no. 7, pp. 1375\u20131382, Jul. (2021). https:\/\/doi.org\/10.1136\/GUTJNL-2020-322786","DOI":"10.1136\/GUTJNL-2020-322786"},{"key":"46246_CR26","doi-asserted-by":"publisher","unstructured":"Hagstr\u00f6m, H., Vessby, J., Ekstedt, M. & Shang, Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J. Hepatol.80 (2), e76\u2013e77. https:\/\/doi.org\/10.1016\/J.JHEP.2023.08.026 (Feb. 2024).","DOI":"10.1016\/J.JHEP.2023.08.026"},{"key":"46246_CR27","unstructured":"Svensk, F. & Patologi Svensk F\u00f6rening f\u00f6r Klinisk Cytologi. Accessed: Apr. 04, [Online]. (2019). Available: https:\/\/www.svfp.se\/foreningar\/uploads\/L15178\/kvast\/lever\/Leverbiopsier2019.pdf"},{"key":"46246_CR28","doi-asserted-by":"publisher","unstructured":"McPherson, S. et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J. Hepatol.62 (5), 1148\u20131155. https:\/\/doi.org\/10.1016\/j.jhep.2014.11.034 (May 2015).","DOI":"10.1016\/j.jhep.2014.11.034"},{"key":"46246_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson, J. F. et al. External review and validation of the Swedish national inpatient register. BMC Public. Health. 11, 450. https:\/\/doi.org\/10.1186\/1471-2458-11-450 (2011).","journal-title":"BMC Public. Health"},{"key":"46246_CR30","doi-asserted-by":"publisher","unstructured":"Yuan, S. et al. Older age of celiac disease diagnosis and risk of autoimmune disease: A nationwide matched case-control study. J. Autoimmun.143https:\/\/doi.org\/10.1016\/J.JAUT.2024.103170 (Feb. 2024).","DOI":"10.1016\/J.JAUT.2024.103170"},{"key":"46246_CR31","doi-asserted-by":"publisher","unstructured":"Wettermark, B. et al. Jul., The new Swedish Prescribed Drug Register\u2014Opportunities for pharmacoepidemiological research and experience from the first six months, Pharmacoepidemiol. Drug Saf., vol. 16, no. 7, pp. 726\u2013735, (2007). https:\/\/doi.org\/10.1002\/PDS.1294","DOI":"10.1002\/PDS.1294"},{"key":"46246_CR32","doi-asserted-by":"publisher","unstructured":"Ludvigsson, J. F., Svedberg, P., Ol\u00e9n, O., Bruze, G. & Neovius, M. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur. J. Epidemiol.34 (4), 423\u2013437. https:\/\/doi.org\/10.1007\/S10654-019-00511-8\/FIGURES\/6 (Mar. 2019).","DOI":"10.1007\/S10654-019-00511-8\/FIGURES\/6"},{"key":"46246_CR33","doi-asserted-by":"publisher","unstructured":"Putter, H., Fiocco, M. & Gekus, R. B. Tutorial in biostatistics: competing risks and multi-state models. Stat. Med.26 (11), 2389\u20132430. https:\/\/doi.org\/10.1002\/SIM.2712 (May 2007).","DOI":"10.1002\/SIM.2712"},{"key":"46246_CR34","doi-asserted-by":"publisher","unstructured":"De Vries, M., Westerink, J., Kaasjager, K. H. A. H. & De Valk, H. W. Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. J. Clin. Endocrinol. Metab.105 (12). https:\/\/doi.org\/10.1210\/CLINEM\/DGAA575 (Dec. 2020).","DOI":"10.1210\/CLINEM\/DGAA575"},{"key":"46246_CR35","doi-asserted-by":"publisher","unstructured":"Zou, Z. Y., Shen, B. & Fan, J. G. Systematic Review with Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease, Inflamm. Bowel Dis., vol. 25, no. 11, pp. 1764\u20131772, Oct. (2019). https:\/\/doi.org\/10.1093\/IBD\/IZZ043.","DOI":"10.1093\/IBD\/IZZ043"},{"key":"46246_CR36","doi-asserted-by":"publisher","unstructured":"Hoffmann, P., Jung, V., Gauss, A. & Behnisch, R. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis, World J. Gastroenterol., vol. 26, no. 46, pp. 7367\u20137381, Dec. (2020). https:\/\/doi.org\/10.3748\/WJG.V26.I46.7367.","DOI":"10.3748\/WJG.V26.I46.7367"},{"key":"46246_CR37","doi-asserted-by":"publisher","unstructured":"Reilly, N. R., Lebwohl, B., Hultcrantz, R., Green, P. H. R. & Ludvigsson, J. F. Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease, J. Hepatol., vol. 62, no. 6, pp. 1405\u20131411, Jun. (2015). https:\/\/doi.org\/10.1016\/j.jhep.2015.01.013","DOI":"10.1016\/j.jhep.2015.01.013"},{"key":"46246_CR38","doi-asserted-by":"publisher","unstructured":"Valvano, M. et al. Celiac disease, gluten-free diet, and metabolic and liver disorders, Nutrients, vol. 12, no. 4, Apr. (2020). https:\/\/doi.org\/10.3390\/NU12040940.","DOI":"10.3390\/NU12040940"},{"key":"46246_CR39","doi-asserted-by":"publisher","unstructured":"Yen, F. S., Huang, J. Y., Lin, S. Y., Liao, P. L. & Wei, J. C. C. Maternal autoimmune disease associated with a higher risk of offspring with type 1 diabetes: A nationwide mother-child cohort study in Taiwan. Diabetes Metab.49 (3). https:\/\/doi.org\/10.1016\/j.diabet.2023.101443 (May 2023).","DOI":"10.1016\/j.diabet.2023.101443"},{"key":"46246_CR40","doi-asserted-by":"publisher","unstructured":"Shao, Y. H. J. & Chen, Y. M. Parental autoimmunity and offspring risks of rheumatic diseases: a nationwide population-based study, Rheumatology (Oxford)., vol. 63, no. 8, pp. 2189\u20132198, Aug. (2024). https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEAD562","DOI":"10.1093\/RHEUMATOLOGY\/KEAD562"},{"key":"46246_CR41","doi-asserted-by":"publisher","unstructured":"Neuhausen, S. L. et al. Sep., Co-occurrence of celiac disease and other autoimmune diseases in celiacs and their first-degree relatives, J. Autoimmun., vol. 31, no. 2, p. 160, (2008). https:\/\/doi.org\/10.1016\/J.JAUT.2008.06.001","DOI":"10.1016\/J.JAUT.2008.06.001"},{"key":"46246_CR42","doi-asserted-by":"publisher","unstructured":"Zhang, Q. et al. Apr., Long-Term Risk of Inflammatory Bowel Disease With MASLD: A Large-Scale Prospective Cohort Study in UK Biobank, Journal of Gastroenterology and Hepatology (Australia), (2025). https:\/\/doi.org\/10.1111\/JGH.16880","DOI":"10.1111\/JGH.16880"},{"key":"46246_CR43","doi-asserted-by":"publisher","unstructured":"Zhang, Q. et al. Jul., Non-alcoholic fatty liver degree and long-term risk of incident inflammatory bowel disease: A large-scale prospective cohort study, Chin. Med. J. (Engl)., vol. 137, no. 14, pp. 1705\u20131714, (2024). https:\/\/doi.org\/10.1097\/CM9.0000000000002859.","DOI":"10.1097\/CM9.0000000000002859"},{"key":"46246_CR44","doi-asserted-by":"publisher","unstructured":"Chen, J. et al. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn\u2019s disease but not Ulcerative Colitis: a prospective cohort study. Hepatol. Int.17 (1), 202\u2013214. https:\/\/doi.org\/10.1007\/S12072-022-10424-6 (Feb. 2023).","DOI":"10.1007\/S12072-022-10424-6"},{"key":"46246_CR45","doi-asserted-by":"publisher","unstructured":"Bergman, D. et al. Incidence and prevalence of autoimmune disease in the Swedish National Patient Register. Eur. J. Epidemiol.https:\/\/doi.org\/10.1007\/s10654-026-01369-3 (Feb. 2026).","DOI":"10.1007\/s10654-026-01369-3"},{"key":"46246_CR46","doi-asserted-by":"publisher","unstructured":"Hagstr\u00f6m, H. et al. Maternal obesity increases the risk and severity of NAFLD in offspring, J. Hepatol., vol. 75, no. 5, pp. 1042\u20131048, Nov. (2021). https:\/\/doi.org\/10.1016\/j.jhep.2021.06.045","DOI":"10.1016\/j.jhep.2021.06.045"},{"key":"46246_CR47","doi-asserted-by":"publisher","unstructured":"Issa, G., Shang, Y., Strandberg, R., Hagstr\u00f6m, H. & Wester, A. Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden. J. Hepatol.0 (0). https:\/\/doi.org\/10.1016\/J.JHEP.2025.03.001 (Mar. 2025).","DOI":"10.1016\/J.JHEP.2025.03.001"},{"key":"46246_CR48","doi-asserted-by":"publisher","unstructured":"Shang, Y. et al. Risk of infections in non-alcoholic fatty liver disease: A nationwide population-based cohort study, Liver Int., vol. 43, no. 10, pp. 2142\u20132152, Oct. (2023). https:\/\/doi.org\/10.1111\/LIV.15680","DOI":"10.1111\/LIV.15680"},{"key":"46246_CR49","doi-asserted-by":"publisher","unstructured":"Ebrahimi, F. et al. Dec., Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease - A Population-based Cohort Study, Clin. Gastroenterol. Hepatol., vol. 21, no. 13, pp. 3346\u20133355.e19, (2023). https:\/\/doi.org\/10.1016\/J.CGH.2023.05.013","DOI":"10.1016\/J.CGH.2023.05.013"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46246-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46246-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46246-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:39:33Z","timestamp":1781645973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46246-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46246"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46246-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12217"}}